Some possible molecular mechanisms of VEGF encoding plasmids functioning
A S Grigorian, , K G Schevchenko
Genes & Cells ›› 2011, Vol. 6 ›› Issue (3) : 24 -28.
Some possible molecular mechanisms of VEGF encoding plasmids functioning
Gene therapeutic approaches to the restoration of theischemic tissue perfusion are considered very promising,but to this time the molecular mechanisms which allow thetherapeutic gene encoding plasmid to transfect the targetcell and underlie the positive clinical effects remain unknown.In this review the possible molecular mechanisms of theangiogenic factor VEGF encoding plasmid penetration into thecytoplasm and the nucleus of the target cell are discussed,and also the methods for better transfection and the gene ofinterest expression are proposed.
| [1] |
Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003; 9: 669-76. |
| [2] |
Ferraro B., Cruz Y.L., Baldwin M., Coppola D., Heller R. Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Therapy 2010; 17: 763-9. |
| [3] |
Nikol S. Viral or non-viral angiogenesis gene transfer - New answers to old questions. Cardiovasc. Res. 2007; 73: 443-5. |
| [4] |
Sylven C. Angiogenic gene therapy. Drugs of today 2002; 38: 819-27. |
| [5] |
Деев Р.В., Григорян А.С., Потапов И.В. и др. Мировой опыт и тенденции генной терапии ишемических заболеваний. Ангиология и сосуд. хирургия 2011; 17 (2): 145-54. |
| [6] |
Wiley Gene Therapy Clinical Trials Worldwide. http://www.wiley. com/legacy/wileychi/genmed/clinical/ |
| [7] |
Douglas J. Adenoviral vectors for gene therapy. Mol. Biotechnol. 2007; 36 (1): 71-80. |
| [8] |
Yang Y., Wilson J.M. Clearance of adenovirus-infected hepatocytes by MHC class I restricted CD4+ CTLs in vivo. J. Immunol. 1995; 155: 2564-9. |
| [9] |
Melillo G., Scoccianti M., Kovesdi I. et al. Gene therapy for collateral vessel development. Cardiovasc. Res. 1997; 35: 480-9. |
| [10] |
Williams P.D., Ranjzad P., Kakar S.J. Development of viral vectors for use in cardiovascular gene therapy. Viruses 2010; 2: 334-71. |
| [11] |
Harris J.D., Lemoine N.R. Strategies for targeted gene therapy. Trends Genet. 1996; 12: 400-5. |
| [12] |
Sinn P.L., Sauter S.L., McCray P.B. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Therapy 2005; 12: 1089-98. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
